Alignment Healthcare Inc

ALHC remains in a Stage 2 advancing regime with higher highs and higher lows supporting a medium-term bullish bias, anchored by a rising 50 DMA. Although the recent Bullish Exhaustion suggests waning upside momentum and price is testing the 9/21 EMAs, an active Lockout Rally confirms underlying demand and justifies immediate participation. Buy Now into shallow pullbacks toward the short EMA zone, seeking a reclaim and acceptance above the 9/21 EMAs. A decisive break below the 50 DMA or failure to hold the EMAs would invalidate this bullish stance.

• ↑Membership grew 31% YoY to 284.8K; Q1 2026 revenue rose 33% to $1.2B.
• ↑Q1 adjusted EBITDA reached $38M (3.1% margin), up 88% YoY; cash $726M.
• ↓Securities fraud probe and whistleblower suit triggered a 16.7% share price drop.